drug
levomilnacipran hydrochloride ER
Marketedupdated 2mo agoby Prinston Pharmaceutical Inc
Approvedcommunity read0 votes
indications
investigational
Major Depression
all catalysts(0)
nothing on the calendar yet
Trials studying levomilnacipran hydrochloride ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 2, 2031
~4.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- May 23, 2032compositionUS 8865937
- May 23, 2032compositionUS 8865937
- May 23, 2032compositionUS 8865937
- May 23, 2032compositionUS 8865937
- Mar 2, 2031method-of-use (U-839)US 84815984.6y
- Mar 2, 2031method-of-use (U-839)US 84815984.6y
- Mar 2, 2031method-of-use (U-839)US 84815984.6y
- Mar 2, 2031method-of-use (U-839)US 84815984.6y
- Jan 11, 2026method-of-use (U-839)US RE43879
- Jan 11, 2026method-of-use (U-839)US RE43879
- Jan 11, 2026method-of-use (U-839)US RE43879
- Jan 11, 2026method-of-use (U-839)US RE43879
FDA exclusivities (4)
- Mar 24, 2026M-304Method (3y)
- Mar 24, 2026M-304Method (3y)
- Mar 24, 2026M-304Method (3y)
- Mar 24, 2026M-304Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that